Skip to main content

Apellis Pharmaceuticals, Inc.

corporate_fare Company Profile

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed APLS - Latest Insights

APLS
Apr 14, 2026, 7:40 AM EDT
Filing Type: SC 14D9
Importance Score:
10
APLS
Apr 14, 2026, 7:02 AM EDT
Filing Type: SC TO-T
Importance Score:
10
APLS
Apr 06, 2026, 6:08 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
APLS
Apr 06, 2026, 4:02 PM EDT
Filing Type: SC14D9C
Importance Score:
7
APLS
Mar 31, 2026, 5:30 PM EDT
Filing Type: SC14D9C
Importance Score:
10
APLS
Mar 31, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
10
APLS
Mar 31, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
APLS
Mar 31, 2026, 5:01 PM EDT
Filing Type: SC TO-C
Importance Score:
10
APLS
Mar 31, 2026, 7:19 AM EDT
Source: Reuters
Importance Score:
9
APLS
Feb 24, 2026, 6:56 AM EST
Filing Type: 10-K
Importance Score:
8
APLS
Jan 12, 2026, 4:52 PM EST
Filing Type: 8-K
Importance Score:
8